Skip to main content
. Author manuscript; available in PMC: 2009 Sep 27.
Published in final edited form as: Lancet Neurol. 2008 Jul 28;7(9):805–811. doi: 10.1016/S1474-4422(08)70170-4

Table 1.

Current randomised, double-blind, parallel-assignment studies of immunotherapy in Alzheimer’s disease

Phase Intervention Primaryoutcomes Size Duration
Active immunisation
NCT00498602 Phase II ACC-001+QS21 vs ACC-001 vs placebo Safety, tolerability 228 Nov, 2007, to March, 2012
NCT00411580 Phase I CAD106 Safety, tolerability 60 June, 2005, to April, 2008
NCT00464334 Phase I V950 Safety 70 April, 2007, to Sept, 2011
Passive immunisation
NCT00575055 Phase III Bapineuzumab Cognitive, functional 800 Dec, 2007, to Dec, 2010
NCT00329082 Phase II LY2062430 Safety, tolerability 25 May, 2006, to May, 2008
NCT00299988 Phase II Intravenous immunoglobulin ADAS-cog,ADAS-CGIC 24 Start Feb, 2006; ongoing but recruitment complete
NCT00455000 Phase I PF-04360365 Safety, tolerability, pharmacokinetics 36 March, 2007, to June, 2008
NCT00531804 Phase I R1450 Adverse events, laboratory measures, vital signs 80 Dec, 2006, to Jan, 2009

ADAS-cog/CGIC=Alzheimer’s disease assessment score cognitive scale/clinician’s global impression of change.